California, USA – 2 October 2015 – Clarient Diagnostic Services, Inc. a division of GE Healthcare (NYSE:GE) announced it will be offering the FDA approved PD-L1 companion diagnostic which will help identify patients most likely to benefit from Merck’s newly-approved lung cancer drug, Keytruda.
http://www.genewsroom.com/press-releases/precise-diagnosis-precision-lung-cancer-drug-ge-healthcare%E2%80%99s-clarient-diagnostics